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Edited by Judit OvadiAbstract Using a number of intramolecularly quenched ﬂuor-
ogenic (IQF) substrates encompassing the subtilisin kexin
isozyme-1 (SKI-1)-mediated cleavage sites of various viral
glycoproteins, it is revealed that 4-[2-Aminoethyl Benzene]
SulfonylFluoride (AEBSF) can inhibit the proteolytic activity
of SKI-1 mostly in a competitive manner. The measured IC50
values range from 200 to 800 nM depending on the nature of the
substrate used. This is the ﬁrst in vitro demonstration of a non-
peptide inhibitor of SKI-1. In an eﬀort to enhance the selectivity
and potency of SKI-1 inhibition, a hexapeptidyl derivative
containing SKI-1 consensus sequence, Ac-Val-Phe-Arg-Ser-Leu-
Lys-AEBSF, was prepared. The peptide sequence was derived
from the primary auto-activation site of prodomain of SKI-1
itself terminating at Leu-Lys138 and contains the crucial P4-basic
and P2 alkyl side chain containing hydrophobic amino acids.
Like AEBSF, the hexapeptidyl-AEBSF analog blocked SKI-1
cleavages of all IQF-substrates tested but with enhanced
eﬃciency.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.1. Introduction
Generation of bioactive proteins and polypeptides via
cleavage of their inactive precursors after mono or paired basic
residues is a wide spread process [1]. Less common is the recent
ﬁnding that functionally active molecules can also be generated
by selected proteolysis after either hydrophobic or small amino
acid (aa) [2]. Subtilisin kexin isozyme-1 (SKI-1) [3] also known* Corresponding author. Fax: +1-613-761-4355.
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Abbreviations: PC, proprotein convertase; SKI-1, subtilisin kexin
isozyme-1, S1P, site 1 protease; vv, vaccinia virus; aa, amino acid(s); h,
human;m,mouse; r, rat;MALDI-TOF,matrix-assisted laser desorption
ionization-time of ﬂight; Fmoc,N-(9-ﬂuorenyl)-methoxycarbonyl; IQF,
intramolecularly quenched ﬂuorogenic; RP-HPLC, reverse phase high-
performance liquid chromatography; Tyx, 3-nitro tyrosine; Abz,
2-aminobenzoic acid; TFA, triﬂuoroacetic acid; Dabcyl, 4-40-dimethyl
amino phenazo benzoic acid; Edans, 5-[(20-amino ethyl)-amino] naph-
thalene 1-sulfonic acid; PyBop, benzotriazol-1-yl-oxytripyrrolidino-
phosphonium hexaﬂuorophosphate; HOBT, 1-hydroxybenzotriazole
hydrate; Tris, Tris hydroxymethyl amino methane; Mes, 1-morpholino
ethane sulfonic acid; cmv, cytomegalovirus
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lase with such substrate speciﬁcity. It is a widely expressed
enzyme with various functional roles [3–5]. SKI-1 is a Ca2þ-
dependent protease that cleaves protein precursors at the C-
terminus of a non-basic amino acid within the sequence motif
Arg/Lys-X-/-Leu/Ser/Thr#, where X is any amino acid except
Cys and / is the alkyl side chain containing hydrophobic
amino acid. SKI-1 is a subtype of basic amino acid cleaving
enzymes called proprotein convertases (PCs) [1,2]. SKI-1 be-
longs to pyrolysin branch of subtilases compared to PCs that
are within the kexin branch. So far, ﬁve physiological sub-
strates of SKI-1 have been identiﬁed. These are proBDNF [3],
SREBPs [4,6], the transcription factor ATF-6 [7,8], SREBP
cleavage-activating protein involved in cartilage development
in zebra ﬁsh [9] and the prodomain of SKI-1 itself [5]. Based on
functional roles of some of these SKI-1 substrates, various
cellular and biochemical studies, SKI-1 has been implicated in
cholesterol metabolism, fatty acid synthesis, ER (endoplasmic
reticulum) induced stress regulation and cartilage growth and
development. Recent studies further indicated that this cellular
protease also participates in the proteolytic activation of viral
coat glycoproteins of highly infectious Lassa [10], lymphocytic
choriomeningitis [11], and crimean congo hemorrhagic fever
(CCHF) [12] viruses, suggesting its role in these pathogeneses.
Owing to these ﬁndings, we became interested to develop small
molecule inhibitors of SKI-1 that may ﬁnd potential applica-
tions as therapeutic agents. Studies have so far revealed that
the prodomain of SKI-1 and its derived peptides [5] and sev-
eral bio-engineered forms of a1-antitrypsin containing the
SKI-1 motif 379RILL, RRLL or RRLV replacing the wild type
sequence 379AIPM in the reactive site loop of this serpin [13]
are able to inhibit SKI-1 mediated processing of SREBPs in
cell based assay. Okada et al. [14] recently reported that the
non-peptide general serine protease inhibitor 4-(2-Aminoethyl)
Benzene Sulphonyl Fluoride (AEBSF) [15] prevented ER
stress-induced SKI-1-mediated cleavage of activating tran-
scription factor 6 (ATF6a and b). It also inhibited the pro-
duction of active form of SREBP-2 that was induced in
response to sterol depletion. Both results indicated that AE-
BSF is an ex vivo SKI-1 inhibitor. In order to conﬁrm this
ﬁnding, and as part of our ongoing eﬀorts to develop potent
and selective small molecule inhibitors of SKI-1, we have now
carried out in vitro studies using recombinant SKI-1 and a
number of synthetic ﬂuorogenic SKI-1 substrates. These sub-blished by Elsevier B.V. All rights reserved.
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viral glycoproteins such as Lassa [10,16] and CCHF [12].
AEBSF, available in the form of its hydrochloride salt known
as Pefabloc, SC is described as a serine protease inhibitor and
an ideal substitute of phenylmethylsulfonyl ﬂuoride (PMSF)
and diisopropyl ﬂuorophosphate (DFP) [17–20] due to its
much lower toxicity, better stability at physiological pH and
capacity to inhibit a broad range of serine proteases. This in-
cludes trypsin, chymotrypsin, plasmin, plasma kallikrein,
thrombin, glandular kallikrein, tissue plasminogen activator,
and subtilisin. Among other less known proteases, mention
may be made of Proteinase K and serine threonine phospha-
tase [19,21]. It is mostly used to block unwanted detrimental
eﬀects of proteases during preparative protein puriﬁcation.
[19]. Depending on concentration and pH conditions, AEBSF
can inhibit proteases in a reversible or irreversible manner [17–
20]. In this study, we describe the SKI-1 inhibitory property of
both AEBSF and its hexapeptidyl derivative that contains a
SKI-1 recognition sequence which is likely to enhance the
potency and selectivity of enzyme inhibition.2. Materials and methods
2.1. Materials
4-(2-Aminoethyl) benzene sulfonyl ﬂuoride was purchased as its
hydrochloride salt from Fisher Scientiﬁc (Nepean, ON, Canada), while
the intramolecularly quenched peptides were either bought from Ba-
chem Chemical (King of Prussia, PA, USA) or synthesized in the
laboratory. All N-(9-ﬂuorenyl)-methoxycarbonyl (Fmoc) protected
amino acids (L-conﬁguration), the coupling reagents, HATU (O-h-
exaﬂuorophospho-[7-azabenzotriazol-1-yl]-N,N,N0,N0-tetramethyluro-
nium), DIEA (diisopropyl ethyl amine), Fmoc-PAL-PEG-PS resin and
the solvents were purchased from Applied Biosystems (Foster city, CA,
USA), Calbiochem Novabiochem AG (San Diego, CA, USA), Chem-
Impex International (Wood Dale, IL, USA) and Aldrich Chemical
(Milwaukee, WI, USA). The 2-chlorotritylchloride resin was obtained
from Calbiochem-Novabiochem AG. Amino acid analyses were per-
formed following 24 h hydrolysis in 6 M HCl at 110 C in a sealed tube
using a Dionex BioLC system (model ICS-2500) equipped with an
AminoPacTM PA10 (Dionex, Oakville, ON, Canada) anion-exchange
analytical column and an electrochemical detector (www.dionex.com).
2.2. Peptide synthesis
Various intramolecularly quenched ﬂuorogenic (IQF) peptide sub-
strates used in this study are listed in Table 1. The C-terminal (CT) end
of each peptide is in the amide form unless speciﬁed otherwise. Except
4-40-dimethyl amino phenazo benzoic acid-cytomegalovirus-5-[(20-
amino ethyl)-amino] naphthalene 1-sulfonic acid (Dabcyl-cmv-Edans)
peptide, which was purchased from Bachem, all were synthesized on an
automated solid phase peptide synthesizer (Pioneer model, PE-
PerSeptive Biosystems, Framingham, MA, USA), following HATU/
DIEA-mediated Fmoc chemistry and Fmoc protected unloaded PAL-
PEG-PS (polyamino linker polyethylene glycol polystyrene) resin [16].
For incorporation of hydrophobic amino acids, Val, Leu, Tyr, 3-nitro
tyrosine (Tyx), Abz (2-amino benzoic acid) and hydroxy amino acidsTable 1
Inhibition parameters of AEBSF and its hexa-peptidyl derivative against SK
Inhibitor Substrate Sequen
AEBSF Q-GPC251–263 Abz-D
Dab-cmv-Edans638–648 Dabcy
Q-CCHFV-A512–523 Abz-S
Ac-Val-Phe-Arg-Ser-Leu-Lys-AEBSF Q-GPC251–263 Abz-D
aAll IC50 values were measured with 50 lMﬁnal concentration of the substrat
experiments. Both Q-GPC and Q-CCHFV-A peptides were prepared as desc
Bachem Chemical [23].like Thr and Ser into the elongating peptide chain, an extended cycle
(45 min) with or without a double coupling step was performed instead
of normal standard (20 min) or fast (10 min) cycle. The following side
chain protecting groups were used; pbf (2,2,4,6,7-pentame-
thyldihydrobenzofuran-5-sulfonyl) for Arg; tBut (tertiary butyl) for
Ser and tBoc (tertiary butyloxy carbonyl) for Lys.
2.3. Peptide puriﬁcation
Crude peptides were puriﬁed by reverse phase high-performance li-
quid chromatography (RP-HPLC) on a Rainin Dynamax instrument
equipped with SD-1 pump (Rainin Instrument, Emeryville, CA, USA),
using a 10 lm, 300 A C18 column {Jupiter, Phenomenex, column size:
0.46 25 cm (analytical) or 1 25 cm (semipreparative)}. The buﬀer
system comprised of an aqueous 0.1% (v/v) TFA solution and an or-
ganic phase of CH3CN containing 0.1% (v/v) TFA. Peptides were
eluted with a 1% min1 linear gradient (5–60%) of 0.1% aqueous TFA/
CH3CN at a ﬂow rate adjusted to 1 mL/min (analytical run) or 2 mL/
min (semipreparative run), following a 5 min isocratic at 5% of 0.1%
TFA/CH3CN. The elution of the peptides was monitored on line by
measurement of UV absorbency with wavelength set at 214 nm and/or
ﬂuorescence measurement at excitation and emission wavelengths ﬁxed
at 320 and 420 nm for Abz and nitro tyrosine pair or 355 and 495 nm
for Dabcyl and Edans pair, respectively.
2.4. Matrix-assisted laser desorption time-of-ﬂight (MALDI-TOF)
mass spectrometry
All MALDI-TOF mass spectra were recorded using 1–2 lL sample
and an identical volume of a saturated solution of CHCA (a-cyano-4-
hydroxycinnamic acid) or DHB, (1,2 dihydroxy benzoic acid) using
Voyager DE (PE Biosystem, Framingham, MA, USA) instrument [16].
2.5. Synthesis of peptidyl-AEBSF
The peptide selected for conjugation to AEBSF for development of a
SKI-1 inhibitor is the hexamer, Val-Phe-Arg-Ser-Leu-Lys. This se-
quence easily recognized by SKI-1 is derived from the region of pri-
mary activation site in the prodomain of SKI-1 itself [3–5]. Initially,
the protected hexapeptide, H2N-Val-Phe-Arg(Pbf)-Ser(tBt)-Leu-Lys(-
Boc)-COOH (1 mM scale), was prepared by solid phase Fmoc chem-
istry using the unloaded 2-chlorotritylchloride resin [22]. Acetylation
was performed directly on the resin by the addition of 5% acetic an-
hydride and 2.1 equivalent DIEA (diisopropyl ethyl amine) in DCM
(Dichloromethane) and shaking at 25 C for 30 min. Excess reagent
was removed by ﬁltration and the peptide was carefully cleaved from
the acid sensitive resin by treatment with acetic acid/triﬂuoro ethanol
(TFE)/DCM (1:1:8) for 10 min and ﬁltered into a receiving ﬂask
containing hexane. The procedure was repeated three times to ensure a
complete release of the protected peptide from the resin. The combined
ﬁltrates in hexane were dried by rotary evaporator with further addi-
tion of hexane to azeotropically remove the acetic acid. The identity of
the peptide was conﬁrmed by MALDI-TOF mass spectrometry [ob-
served m/z¼ 1212 (M+Na)þ, calculated m/z¼ 1211] and amino acid
analysis [16]. The protected peptide (30 mg, 0.025 mmol) was next
activated with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexa-
ﬂuorophosphate (PyBop; 50 mg, 0.1 mmol), 1-hydroxybenzotriazole
hydrate (HOBT; 15 mg, 0.1 mmol) and DIEA (175 lL) in DMF
(2 mL) at room temperature for 1 h. AEBSF.HCl (25 mg, 0.1 mmol)
in DMF (2 mL) was added dropwise and stirred for 30 min. The re-
action was monitored by thin layer chromatography. When judged
complete (6 h), the solution was acidiﬁed with TFA in an ice bath. The
product was recovered by preparative thin layer chromatography
(TLC) and RP-HPLC and fully characterized by MALDI-TOF massI-1 activity as measured with various ﬂuorogenic substrates
ce aIC50 (nM) Ki (nM)
IYISRRLL259#GTFT-Tyx-A 758 231
l-RGVVNA643#SSRLA-Edans 277 120
SGSRRLL519#SEES-Tyx-A 850 250
IYISRRLL259#GTFT-Tyx-A 150 57.7
e. The values were derived from the average of at least two independent
ribed by us [12,16], while Dab-cmv-Edans peptide was obtained from
188 S. Basak et al. / FEBS Letters 573 (2004) 186–194spectrometry {observed m/z¼ 958 (M+H–H2O), 976 (M+H)þ,
998 (M+Na)þ, calculated m/z¼ 975 (M+H)þ} and by amino acid
analysis as described earlier and in [16].
2.6. Source of recombinant SKI-1
The secreted soluble form of hSKI-1 used in this study was obtained
by using a BTMD (Before Trans-Membrane Domain) hSKI-1 con-
struct ending at PGRYNQE997 as previously described [3,5,16]. Fol-
lowing a 6 h infection of vaccinia virus (vv) infected BTMD SKI-1
construct in HK-293 cells, the conditioned medium containing active
SKI-1 was concentrated (15-fold) using centricon-30 (Amicon,
USA), dialyzed and stored with 40% glycerol at )20 C before use. The
sample thus obtained was reasonably pure enzymatic wise. However,
in order to compensate the eﬀect of any contaminant and non-speciﬁc
activity, each experiment was compared with the control, done in
parallel with the medium obtained similarly from the expression of the
empty vector.
2.7. Inhibition study
All enzymatic assays against recombinant SKI-1 were performed
using either initial rate and/or stopped-time assays at 37 C in a ﬁnal
volume of 100 lL in 96-wells ﬂat bottom black plates (Microﬂuor,
Dynatec Laboratories Inc., Rochester, NY, USA). The assays were
performed in a buﬀer consisting of 25 mM Tris + 25 mM 1-mor-
pholino ethane sulfonic acid (Mes) + 2.5 mM CaCl2, pH 7.4. All SKI-
1 assays were performed unless mentioned otherwise using a ﬁnal
concentration of 50 lM of each IQF substrate indicated below. (i)
Lassa virus glycoprotein derived peptide Q-GPC251–263: Abz-251Asp-
Ile-Tyr-Ile-Ser-Arg-Arg-Leu-Leu#Gly-Thr-Phe-263Thr-Tyx-Ala [16],
(ii) cmv protease derived peptide Dabcyl-cmv-Edans638–648: Dabcyl-
638Arg-Gly-Val-Val-Asn-Ala#Ser-Ser-Arg-Leu-648Ala-Edans [23], and
(iii) the site A of glycoprotein of Crimean-Congo Hemorrhagic Fever
Virus derived peptide Q-CCHFV-A512–523: Abz-512Ser-Ser-Gly-Ser-
Arg-Arg-Leu-Leu#Ser-Glu-Glu-523Ser-Tyx-Ala [12]. While both GPC
and CCHFV ﬂuorogenic peptides were developed previously by us,
the cmv-peptide was purchased from Bachem Chemical. For mea-
surement of both Ki (inhibition constant) and IC50 (concentration
necessary to achieve 50% inhibition of enzymatic activity) values, the
inhibitor concentrations were varied over a range wide enough to
yield residual activities of 25–75% of the control value. The kinetic
parameters were evaluated using the program Graﬁt (v4.0, Erthacus
Software, Distributor, Sigma Chemical, St. Louis, MO, USA). Stan-
dard curves and quench corrections were performed for accurate
evaluation as described previously [16,24]. Enzyme sample, typically
10 lL of hSKI-1, was used for each assay. To these were added in-
creasing concentrations of inhibitors ranging from 20 to 2500 lM in a
total volume of 100 ll of buﬀer solution as described above, in a 96-
well plate at 37 C. Following a 15 min pre-incubation, substrate
solution (5 lL) was added and the sample was incubated again. The
rate of substrate hydrolysis was obtained from changes in ﬂuores-
cence readings and the values transformed into amounts of lM/h of
peptide cleaved by using the standard curve and quenching correc-
tions as described in [24]. Non-linear regression of plots of hydrolysis
rate vs. the inhibitor concentration was used for three sets of each
substrate concentration. Data were collected in duplicates and each
value is the mean of two independent experiments. For determination
of site of cleavage, each digest was analyzed by RP-HPLC using a C18
analytical column followed by MALDI-TOF-MS of each isolated
peak.Fig. 1. Inactivation of proteolytic activity of recombinant human
SKI-1 towards cleavages of Q-GPC251–263 [Abz-DIYISRR
LL259#GTFT-Tyx-A] (A) and Dab-cmv-Edans638–648 Dabcyl-
RGVVNA643#SSRLA-Edans (B) by varying concentrations of
AEBSF.HCl. A 15 min pre-incubation between the enzyme and AE-
BSF is followed by addition of the substrate (50 lM ﬁnal concentra-
tion). The residual enzymatic activity after a period of 150 min was
estimated by measuring the ﬂuorescence intensity at excitation and
emission wave lengths ﬁxed at 320 and 420 nm for Q-GPC251–263 and
355 and 495 nm for Dab-cmv-Edans638–648, respectively. The enzyme
used in this study was obtained from BTMD-SKI-1 construct and is
partially puriﬁed by centricon ﬁltration and dialysis as described in
Section 2. Control experiments were performed with media obtained
similarly from empty vector. Each data point was the representative of
at least two independent experiments carried simultaneously.3. Results
3.1. Eﬀect of AEBSF on SKI-1 mediated cleavage of Q-GPC
We have shown previously that one of the most potent
substrates for in vitro assay of SKI-1 activity is an IQF peptide
Q-GPC [Abz-251Asp-Ile-Tyr-Ile-Ser-Arg-Arg-Leu-Leu#Gly-
Thr-Phe-263Thr-Tyx-Ala], derived from the activation site of
Lassa viral glycoprotein [16]. This peptide was selectively and
eﬃciently cleaved at RRLL259#GTF site by SKI-1 resulting in
the release of ﬂuorescence measured at kex ¼ 320 nm and
kem ¼ 420 nm. To examine the eﬀect of AEBSF on SKI-1activity, Q-GPC was chosen as the initial substrate. Our results
indicate that AEBSF bocks this cleavage in a dose-dependent
manner. As shown in Fig. 1A using 50 lM Q-GPC as the
substrate, the measured IC50 value based on two independent
experiments and correction of peptide content is 758 nM.
Dixon plots using three diﬀerent concentrations (50, 25 and
12.5 lM) of Q-GPC and a 15-min pre-incubation period for
the enzyme to interact with AEBSF before addition of the
substrate showed that the inhibition constant Ki is 231 nM
(Fig. 2, Table 1). It is further noted that the obtained three
regression lines nearly pass through a common point of in-
tersection, suggesting that the inhibition is mostly competitive
and reversible in nature [16,24,25]. Based on the equation
Ki ¼ IC50=ð1þ S=KmÞ where S is the substrate concentration,
Km is the Michaelis–Menten constant, applicable to reversible
and competitive inhibition [26], the estimated Ki for SKI-1
inhibition of Q-GPC cleavage by AEBSF is 61 nM. This is
more than 3-fold lower than the measured value of 231 nM.
This may suggest that this inhibition may not be true com-
petitive and possibly it is more like mixed type of inhibition.
Thus, it is likely that AEBSF interacts with both catalytic and
non-catalytic regions of SKI-1 in which case the above equa-
tion is not fully applicable. The inhibition character remains
mostly unaltered over the range of pre-incubation time (2–15
min) used in this study. This suggests that the formation of the
complex between AEBSF and SKI-1 enzyme is relatively
rapid.
3.2. Eﬀect of AEBSF on SKI-1 mediated cleavage of cmv
peptide
Recent study from our laboratory (Basak et al., in prepa-
ration) indicated that SKI-1 cleaves quite eﬃciently the IQF
peptide, Dab-cmv-Edans638–648 [Dabcyl-RGVVNA643#
SSRLA-Edans], derived from the maturational site of human
(h) cmv protease at the correct physiological site [23]. When
this peptide (50 lM) was used as a substrate for SKI-1, again
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Fig. 2. Dixon plots showing the inhibition of SKI activity by
varying concentrations of AEBSF.HCl as measured against three
diﬀerent concentrations (12.5, 25 and 50 lM) of the substrate, Q-
GPC251–263 [Abz-DIYISRRLL259#GTFT-Tyx-A]. The inhibition
constant Ki was measured from the intersections of any two re-
gression lines and the values were averaged as shown (for details see
Section 2).
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more than 95% of SKI-1 inhibition was achieved with 1 lM
AEBSF and the measured IC50 value was 277 nM (Fig. 1B)
which is nearly 2.7-fold lower than 758 nM value observed
with Q-GPC. The measured Ki value with this substrate based
on Dixon plot (not shown) is 120 nM, nearly 2.3-fold lower
than that for Q-GPC. Mass spectral analysis of 3 h crude di-
gest of Dab-cmv-Edans638–648 indicated that SKI-1 cleaved
Dabcyl-cmv-Edans primarily at the correct NA643#SS physi-
ological site. Thus, MS spectrum showed peaks at (i) 1627Fig. 3. MALDI-TOF mass spectral analyses of 3 h crude digests of Dab-cmv-E
in the presence of various amounts (12.5, 62.5, 125 and 250 nM) of AEBSF.
substrate (Dab-cmv-Edans638–648 (Dabcyl-RGVVNA643#SSRLA-Edans, cal
calculated mass¼ 864). The corresponding CT fragment could not be detect(M+H)þ, 1649 (M+Na)þ for the undigested peptide (calcu-
lated mass¼ 1626), (ii) 866 (M+H)þ, 888 (M+Na)þ for the
N-terminal (NT) fragment Dabcyl-R-G-V-V-N-A-OH (calcu-
lated mass¼ 865) and (iii) 779 (not observed possibly due to
further degradation) for the CT fragment, S-S-R-L-A-Edans
(Fig. 3). Upon prolonged incubation (18 h), a minor cleavage
at Dabcyl-R-G-V-V-N-A-S-S#R-L-A-Edans was also observed
leading to the formation of Dabcyl-R-G-V-V-N-A-S-S-OH [m/
z¼ 1041, (M+H)þ, calculated¼ 1040] (not shown).
A comparison of MALDI-TOFMS data of 3 h crude digests
of Dabcyl-cmv-Edans (10 lg) with an identical amount of
recombinant SKI-1 (10 lL) in the absence and presence of
varying amounts (12.5–250 nM) of AEBSF is shown in Fig. 3.
The ﬁgure shows that as the amount of added AEBSF is in-
creased, there is less formation of cleavage fragment (peak at
m/z¼ 866 for the NT piece) and more of undigested substrate
(peak at m/z¼ 1627), suggesting that AEBSF blocks SKI-1
mediated cleavage of cmv peptide.3.3. Dose-dependent eﬀect of AEBSF on SKI-1 mediated
cleavage of Q-GPC peptide using mass spectra
Similar to that observed with cmv peptide, the cleavage of
Q-GPC peptide by recombinant SKI-1 can also be eﬃciently
hindered in vitro by AEBSF in a concentration-dependent
manner. Thus, as shown by MALDI-TOF MS data in Fig. 4,
with the increase in amount of added AEBSF, the intensity of
the peak for the NT cleavage product (m/z¼ 1268) following 6
h digestion with SKI-1 was gradually diminished while the
peak intensity of the undigested Q-GPC peptide (m/z¼ 1950) is
enhanced. In these experiments, the CT cleaved product at m/
z¼ 702 was not detectable possibly due to further degradation,
lack of charge and high hydrophobicity.dans638–648 (10 lg) by identical amount of recombinant hSKI-1 (10 lL)
HCl. The peaks at m/z 1627 and 866 were attributed to the undigested
culated mass¼ 1626) and the NT fragment (Dabcyl-RGVVNA-OH,
ed under the condition used.
Fig. 4. MALDI-TOF mass spectral analyses of 6 h crude digests of Q-GPC251–263 (10 lg) by identical amount of recombinant hSKI-1 (10 lL) in the
presence of various amounts (12.5, 62.5, 125 and 250 nM) of AEBSF.HCl. The peaks at m/z 1950 and 1268 were attributed to the undigested
substrate, (Q-GPC251–263¼Abz-DIYISRRLL259#GTFT-Tyx-A, calculated mass¼ 1949) and and the NT fragment (Abz-DIYISRRLL-OH, calcu-
lated mass¼ 1267). The corresponding CT fragment could not be detected under the condition used.
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Q-CCHFV-A peptide
Recently, we reported that the envelope surface glycopro-
tein of CCHFV is cleaved at the NT A-site (RRLL519#SE) by
SKI-1, while the other site (C-terminal B-site, RKPL1040#FL)
is cleaved by a non-PC like enzyme [12]. Based on this ob-
servation, we developed an IQF peptide (Q-CCHFV512–523)
derived from the A-site as a substrate for SKI-1 (Table 1). As
shown in this table, A EBSF also prevents the cleavage of Q-
CCHFV512–523 by recombinant SKI-1. A comparison of
measured IC50 value (850 nM) with those obtained with Q-
GPC251–263 and Dab-cmv-Edans638–648 showed that its inhi-
bition by AEBSF is comparable to that for Q-GPC251–263
substrate. We also observed by mass spectra that AEBSF
upon incubation does not react chemically with any of the
substrates used in this study except Q-CCHFV512–523, which
upon prolonged incubation forms a stable chemical adduct
with AEBSF as shown in Fig. 5. Thus, following 18 h in-
cubation it exhibited strong peaks at m/z¼ 1706 and 1891 in
the mass spectrum for the undigested substrate and the
substrate-AEBSF adduct, respectively. The increase of 185
mass unit for the adduct indicates that AEBSF (molecular
weight¼ 203) and the peptide (molecular weight¼ 1706) are
covalently linked to each other by elimination of a molecule
of water. The calculated molecular weight [1706 (mass for
peptide) + 203 (mass for AEBSF))H2O (a molecule of wa-
ter)¼ 1891] is in consistent with the observed value. It is in-
teresting to note that such adduct formation was not
detectable at lower incubation time (less than 4 h) nor with
the two other substrates even after long incubation. It is
presumed that AEBSF may have coupled with either of the
two glutamic acid residues present only in Q-CCHFV-A
substrate.3.5. Synthesis of peptidyl-AEBSF
The chemical synthesis of hexapeptide conjugate of AEBSF,
namely Ac-Val-Phe-Arg-Ser-Leu-Lys-AEBSF, is described
schematically in Fig. 6. The protected hexapeptide acid Ac-
Val-Phe-Arg(Pbf)-Ser(tBut)-Leu-Lys(Boc)-OH, obtained by
solid phase Fmoc chemistry using the unloaded 2-chlorotri-
tylchloride resin (calculated mass¼ 1190, observed¼ 1191),
was conjugated to AEBSF using PyBop/HOBT/DIEA. It was
then fully deprotected with reagent K [16] yielding a complex
mixture which was partially puriﬁed by preparative TLC. The
ﬁnal puriﬁcation was accomplished by RP-HPLC (Fig. 7A).
All HPLC peaks were collected and examined by mass spectra.
The peak eluting at retention time 49.01 min yielded the de-
sired compound Ac-Val-Phe-Arg-Ser-Leu-Lys-AEBSF (mo-
lecular weight calculated¼ 975), observed m/z¼ 976 (M+H)þ,
998 (M+Na)þ, and 958 (M+H–H2O)þ (Fig. 7B). The inset
within B shows the expanded portion of the mass spectrum
near the molecular weight region.
3.6. Eﬀect of Ac-VFRSLK-AEBSF on the activity of SKI-1
When Ac-VFRSLK-AEBSF was pre-incubated for 15 min
with recombinant SKI-1 and the mixture tested for residual
enzyme activity against Q-GPC251–263, there was a signiﬁcant
drop in ﬂuorescence release depending on the concentration of
Ac-VFRSLK-AEBSF used compared to control AEBSF
alone. In fact, addition of 1 lM Ac-VFRSLK-AEBSF com-
pletely abrogated the cleavage of Q-GPC251–263 by re-
combinant SKI-1. The measured IC50 value of 150 nM is
nearly 5-fold lower than AEBSF itself. This suggests that
coupling of AEBSF via its amino terminal to a peptide se-
quence compatible with SKI-1 recognition signiﬁcantly en-
hances SKI-1 inhibition by the resultant molecule. However,
when Ki was determined by using Dixon plots based on end
Fig. 6. It shows the schematic diagram for the synthesis of hexapeptidyl-AEBSF derivative. The ﬁnal product was obtained following complete
deprotection and puriﬁcation by preparative thin-layer chromatography and RP-HPLC in combination as described in Section 2. Synthetic scheme
for pentapeptidyl-AEBSF.
Fig. 5. MALDI-TOF mass spectra of Q-CCHFV-A512–523 (Abz-SSGSRRLL519#SEES-Tyx-A) following incubation at 37 C with equimolar quantity
of AEBSF.HCl in aqueous solution for various lengths of time as indicated. Small aliquots were withdrawn at speciﬁc times for recording the mass
spectra.
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using three separate concentrations of the substrate Q-GPC,
the measured value was 57 nM (Fig. 8, Table 1). The value was
conﬁrmed by two independent experiments. This is 3-fold
higher than that calculated from the equation Ki¼ (IC50/
(1 +S/Km)) valid for true competitive inhibition, where S¼ 50
lM and Km¼ 4.9 lM [16]. This variation again suggests thatlike AEBSF, its peptidyl analog Ac-VFRSLK-AEBSF may
also interact with SKI-1 at multiple sites including the catalytic
(competitive inhibition).
The dose-dependent inhibition of SKI-1 activity by Ac-
VFRSLK-AEBSF as measured against Q-GPC substrate was
also shown by progress curves in Fig. 8B. Clearly, there is a
gradual loss in SKI-1 activity as revealed by the slope of each
Fig. 7. (A) RP-HPLC chromatogram of crude material obtained after
coupling of Ac-V-F-R(Pbf)-S(tBt)-L-K(Boc)-OH with AEBSF, re-
moval of all protecting groups except the acetyl (Ac) group and partial
puriﬁcation by preparative thin-layer chromatography. Various peaks
obtained were collected and examined by MALDI-TOF mass spec-
trometry. The peak with retention time (Rt)¼ 49.01 min was charac-
terized by mass spectrometry (B) as the correct product. (B) The
MALDI-TOF mass spectrum of peak eluting at 49.01 min. It displayed
peaks at m/z 976 and 998 corresponding to the molecular size of Ac-
VFRSLK-AEBSF (calculated mass¼ 975) and its sodium adduct
(calculated mass¼ 997). The peak at m/z¼ 558 was attributed to the
loss of a water (18 mass unit) molecule from the parent molecular ion.
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tidyl-AEBSF.4. Discussions
This study indicates that aromatic sulfonyl ﬂuoride, AEBSF,
is capable of blocking in vitro the proteolytic cleavage of three
synthetic IQF substrates, Q-GPC251–263, Dab-cmv-Edans638–648
and Q-CCHFV512–523 by recombinant SKI-1 (Table 1). The
measured IC50 values in all cases are in medium to high nM
range. Under identical condition, SKI-1 inhibits the cleavage
of Dab-cmv-Edans638–648 2.7 and 3-fold more eﬀectively than
Q-GPC251–263 and Q-CCHFV512–523, respectively. Although
AEBSF was previously described as a general inhibitor of
serine proteases of all sub-types such as trypsin, chymotrypsin,
plasma kallikrein and elastase, no reports are available about
its eﬀect on mammalian subtilases except a recent publication
where it was demonstrated that AEBSF blocks ex vivo the
SKI-1 cleavage of stress responsive transcription factors
ATF6a and b [14]. Since ATF6 plays a major role in unfolded
protein response, this study showed the potential of AEBSF in
this event via its inhibitory action on SKI-1 activity. Our in
vitro study supports the above ex vivo data and is the ﬁrst
direct demonstration of inhibition SKI-1 activity by this non-
peptide AEBSF molecule using small synthetic ﬂuorogenic
substrates. The study also demonstrates that the potency of
inhibition may be substrate dependent, since the most potent
inhibition was observed with Dab-cmv-Edans638–648 followed,respectively, by Q-GPC251–263 and Q-CCHFV512–523. This work
further indicates that in the absence of P4 Arg, SKI-1 can
accept P6-Arg as long as there is P2 and/or P1 alkyl side chain
containing hydrophobic residue – an observation not reported
until recently involving the N-terminal processing of mam-
malian prosomatostatin (PSST) by SKI-1. It was shown that
SKI-1 cleaves PSST at the amino terminal segment 4Asp-Pro-
Arg-Leu-Arg-Gln-Phe-Leu#Gln-Lys-Ser-Leu15, where a single
mutation by Ala of either Arg did not fully abrogate the
cleavage while double mutations caused a complete loss of
cleavage by SKI-1 [27]. Thus, the Arg8 to Ala variant [1Ala-
Pro-Ser-Asp-Pro-Arg-Leu-Ala8-Gln-Phe-Leu#Gln-Lys-Ser-
Leu15] is still processed by SKI-1 though to a reduced level.
This suggests that the presence of Arg at P4 is not an absolute
requirement for recognition by SKI-1 and absence of such
residue can be partly compensated by the presence of P6-Arg
residue. This is in consistent with the present study. Further-
more, our data indicated that the cleavage of a P6-Arg con-
taining substrate such as Dabcyl-cmv-Edans with hydrophobic
Val residues at both P4 and P3 positions is more eﬃciently
blocked by AEBSF compared to substrates that contain P4-
Arg. It may be mentioned that unlike AEBSF, other sulfonyl
ﬂuoride analogs such as PMSF [phenyl-methane-sulfonyl
ﬂuoride] and aPMSF [4-amidino-phenyl-methane-sulfo-
nyl ﬂuoride] were described as poor inhibitors of SKI-1 [5].
This could be related to the presence of aromatic hydrophobic
ring system directly attached to the sulfonyl ﬂuoride moiety
that may interact better with SKI-1 compared to the alkyl
chain attached sulfonyl ﬂuorides. One function of the aryl ring
is to diminish the electrophilicity of attached ﬂuorine atom and
therefore prevent covalent modiﬁcation of the enzyme. It is
likely that such molecules may associate with the catalytic
residues of the enzyme via non-covalent interactions. To our
knowledge, this is only the second report where SKI-1 cleaves
substrates which do not possess a P4-Arg residue but instead
contains a P6-Arg residue and a P4 hydrophobic residue.
Our study also revealed that attachment of a peptide se-
quence compatible with SKI-1 recognition motif such as Val-
Phe-Arg-Ser-Leu-Lys to the amino function of AEBSF led to
an enhancement of SKI-1 inhibition compared to AEBSF
alone. Our initial choice of hexapeptide sequence is based on
the autocatalytic activation site of prodomain of SKI-1 itself
[3–5]. Other sequence motifs (like RSLL#, RRLL# and
RLRQFL#) more notably present in the SKI-1 processing sites
of SREBP-2 [3,4,7], glycoproteins of Lassa [10], CCHF [12]
viruses and PSST (27) could be attached to AEBSF in order to
develop more potent and selective SKI-1 inhibitors. Moreover,
in peptidyl-AEBSF conjugate the aromatic group of AEBSF
moiety may be substituted by a non-aromatic group or none at
all in order to examine the role of aryl group if any on SKI-1
inhibition. Thus, in future study, a tripeptide such as RRL as
well as the tetrapeptide RRLL will be conjugated separately to
AEBSF along with other peptides to understand better the
recognition motif of SKI-1. Among other variations, small
non-aromatic chains mimicking Leu residue may be substi-
tuted to examine their eﬀects on SKI-1 inactivation. Studies
involving a variety of these and other peptidyl aryl and non-
aryl sulfonyl ﬂuorides may provide further insight into the
mechanism of inhibition and also development of novel SKI-1
inhibitors. The formation of a covalent adduct between the Q-
CCHFV-A peptide and AEBSF with the removal of a mole-
cule of water upon prolonged incubation indicated that certain
Fig. 8. (A) Dixon plots showing the inhibition of SKI activity by varying concentrations of Ac-VFRSLK-AEBSF as measured against the substrate,
Q-GPC251–263 [Abz-DIYISRRLL259#GTFT-Tyx-A]. The inhibition constant Ki was measured from the intersections of any two regression lines and
the values were averaged as shown (see Section 2). (B) Progress curves showing the gradual inhibition of SKI-1 activity by various concentrations of
Ac-VFRSLK-AEBSF. The activity of SKI-1 was monitored using Q-GPC (50 lM) as the substrate.
S. Basak et al. / FEBS Letters 573 (2004) 186–194 193substrates, particularly those with multiple acidic amino acids
like Glu, may react with AEBSF and may therefore not be
suitable for monitoring SKI-1 activity.
The mechanism of enzyme inhibition by AEBSF and related
derivatives has been described in the literature. It is now
known that AEBSF rapidly reacts with the catalytic serine
residue, forming a stable acylated enzyme resulting in a loss of
proteolytic activity. The inhibitors may vary in many respects,
including speciﬁcity for particular proteases and the rate at
which they inactivate these proteases. In many cases, non-co-
valent interactions have also been reported [17–20]. It is quite
likely that SKI-1 is also inhibited in a non-covalent manner as
indicated by Dixon plots and progress curves where in many
cases a higher inhibition is noted at the initial period. Another
important ﬁnding of this study is that SKI-1 cleaves in vitro
the synthetic cmv peptide at the correct RGVVNA643#SS
maturational site. This may suggest a possible role of this
enzyme in the activation of cmv protease and hence in the
pathogenesis of this infection. Consequently, SKI-1 speciﬁc
inhibitors may be useful in the intervention of this and other
infections such as Lassa (10), CCHFV (12) where its role has
already been established.5. Conclusion
Our study revealed for the ﬁrst time that a simple aromatic
sulfonyl ﬂuoride (Ar–SO2–F) that inhibits most serine prote-
ases is also capable of inhibiting in vitro the activity of subti-
lase SKI-1. The study also demonstrated that peptidyl
arylsufonyl ﬂuoride may represent a novel class of SKI-1 in-hibitors. The peptide sequence preceding the attached sulfonyl
ﬂuoride moiety is crucial for such inhibition and more studies
involving a variety of peptide sequences and appropriate sul-
fonyl ﬂuoride function are needed for ﬁnal conﬁrmation.
Future study will reveal any potential antiviral and other
biochemical activity of such small molecule based SKI-1
inhibitors.
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